205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
93.02%
Net income growth similar to MCHP's 96.32%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.14%
Some yoy increase while MCHP is negative at -121.69%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
107.56%
Operating cash flow growth above 1.5x MCHP's 35.23%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-49.78%
Negative yoy CapEx while MCHP is 26.11%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
-856.67%
Negative yoy purchasing while MCHP stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
863.64%
Liquidation growth of 863.64% while MCHP is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
1810.00%
Growth of 1810.00% while MCHP is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-123.24%
We reduce yoy invests while MCHP stands at 26.11%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-34.15%
Negative yoy issuance while MCHP is 403.53%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.